Staff

Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience

Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers

YTX-7739 is Yumanity’s lead product candidate in clinical development for the treatment of Parkinson’s diseaseBOSTON, April 22, 2021 (GLOBE NEWSWIRE)...

CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients

Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual MeetingSOUTH SAN...

Data from Codiak’s exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology

– exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo – –...

Therma Bright’s AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P.1 and P.2 and the UK B.1.1.7 Variants

Toronto, Ontario--(Newsfile Corp. - April 22, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the...

error: Content is protected !!